Cargando…
Identification of minimum essential therapeutic mixtures from cannabis plant extracts by screening in cell and animal models of Parkinson’s disease
Medicinal cannabis has shown promise for the symptomatic treatment of Parkinson’s disease (PD), but patient exposure to whole plant mixtures may be undesirable due to concerns around safety, consistency, regulatory issues, and psychoactivity. Identification of a subset of components responsible for...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586206/ https://www.ncbi.nlm.nih.gov/pubmed/36278152 http://dx.doi.org/10.3389/fphar.2022.907579 |
_version_ | 1784813645637615616 |
---|---|
author | Morash, Michael G. Nixon, Jessica Shimoda, Lori M. N. Turner, Helen Stokes, Alexander J. Small-Howard, Andrea L. Ellis, Lee D. |
author_facet | Morash, Michael G. Nixon, Jessica Shimoda, Lori M. N. Turner, Helen Stokes, Alexander J. Small-Howard, Andrea L. Ellis, Lee D. |
author_sort | Morash, Michael G. |
collection | PubMed |
description | Medicinal cannabis has shown promise for the symptomatic treatment of Parkinson’s disease (PD), but patient exposure to whole plant mixtures may be undesirable due to concerns around safety, consistency, regulatory issues, and psychoactivity. Identification of a subset of components responsible for the potential therapeutic effects within cannabis represents a direct path forward for the generation of anti-PD drugs. Using an in silico database, literature reviews, and cell based assays, GB Sciences previously identified and patented a subset of five cannabinoids and five terpenes that could potentially recapitulate the anti-PD attributes of cannabis. While this work represents a critical step towards harnessing the anti-PD capabilities of cannabis, polypharmaceutical drugs of this complexity may not be feasible as therapeutics. In this paper, we utilize a reductionist approach to identify minimal essential mixtures (MEMs) of these components that are amenable to pharmacological formulation. In the first phase, cell-based models revealed that the cannabinoids had the most significant positive effects on neuroprotection and dopamine secretion. We then evaluated the ability of combinations of these cannabinoids to ameliorate a 6-hydroxydopmamine (OHDA)-induced change in locomotion in larval zebrafish, which has become a well-established PD disease model. Equimolar mixtures that each contained three cannabinoids were able to significantly reverse the OHDA mediated changes in locomotion and other advanced metrics of behavior. Additional screening of sixty-three variations of the original cannabinoid mixtures identified five highly efficacious mixtures that outperformed the original equimolar cannabinoid MEMs and represent the most attractive candidates for therapeutic development. This work highlights the strength of the reductionist approach for the development of ratio-controlled, cannabis mixture-based therapeutics for the treatment of Parkinson’s disease. |
format | Online Article Text |
id | pubmed-9586206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95862062022-10-22 Identification of minimum essential therapeutic mixtures from cannabis plant extracts by screening in cell and animal models of Parkinson’s disease Morash, Michael G. Nixon, Jessica Shimoda, Lori M. N. Turner, Helen Stokes, Alexander J. Small-Howard, Andrea L. Ellis, Lee D. Front Pharmacol Pharmacology Medicinal cannabis has shown promise for the symptomatic treatment of Parkinson’s disease (PD), but patient exposure to whole plant mixtures may be undesirable due to concerns around safety, consistency, regulatory issues, and psychoactivity. Identification of a subset of components responsible for the potential therapeutic effects within cannabis represents a direct path forward for the generation of anti-PD drugs. Using an in silico database, literature reviews, and cell based assays, GB Sciences previously identified and patented a subset of five cannabinoids and five terpenes that could potentially recapitulate the anti-PD attributes of cannabis. While this work represents a critical step towards harnessing the anti-PD capabilities of cannabis, polypharmaceutical drugs of this complexity may not be feasible as therapeutics. In this paper, we utilize a reductionist approach to identify minimal essential mixtures (MEMs) of these components that are amenable to pharmacological formulation. In the first phase, cell-based models revealed that the cannabinoids had the most significant positive effects on neuroprotection and dopamine secretion. We then evaluated the ability of combinations of these cannabinoids to ameliorate a 6-hydroxydopmamine (OHDA)-induced change in locomotion in larval zebrafish, which has become a well-established PD disease model. Equimolar mixtures that each contained three cannabinoids were able to significantly reverse the OHDA mediated changes in locomotion and other advanced metrics of behavior. Additional screening of sixty-three variations of the original cannabinoid mixtures identified five highly efficacious mixtures that outperformed the original equimolar cannabinoid MEMs and represent the most attractive candidates for therapeutic development. This work highlights the strength of the reductionist approach for the development of ratio-controlled, cannabis mixture-based therapeutics for the treatment of Parkinson’s disease. Frontiers Media S.A. 2022-10-05 /pmc/articles/PMC9586206/ /pubmed/36278152 http://dx.doi.org/10.3389/fphar.2022.907579 Text en Copyright © 2022 Morash, Nixon, Shimoda, Turner, Stokes, Small-Howard and Ellis. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Morash, Michael G. Nixon, Jessica Shimoda, Lori M. N. Turner, Helen Stokes, Alexander J. Small-Howard, Andrea L. Ellis, Lee D. Identification of minimum essential therapeutic mixtures from cannabis plant extracts by screening in cell and animal models of Parkinson’s disease |
title | Identification of minimum essential therapeutic mixtures from cannabis plant extracts by screening in cell and animal models of Parkinson’s disease |
title_full | Identification of minimum essential therapeutic mixtures from cannabis plant extracts by screening in cell and animal models of Parkinson’s disease |
title_fullStr | Identification of minimum essential therapeutic mixtures from cannabis plant extracts by screening in cell and animal models of Parkinson’s disease |
title_full_unstemmed | Identification of minimum essential therapeutic mixtures from cannabis plant extracts by screening in cell and animal models of Parkinson’s disease |
title_short | Identification of minimum essential therapeutic mixtures from cannabis plant extracts by screening in cell and animal models of Parkinson’s disease |
title_sort | identification of minimum essential therapeutic mixtures from cannabis plant extracts by screening in cell and animal models of parkinson’s disease |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586206/ https://www.ncbi.nlm.nih.gov/pubmed/36278152 http://dx.doi.org/10.3389/fphar.2022.907579 |
work_keys_str_mv | AT morashmichaelg identificationofminimumessentialtherapeuticmixturesfromcannabisplantextractsbyscreeningincellandanimalmodelsofparkinsonsdisease AT nixonjessica identificationofminimumessentialtherapeuticmixturesfromcannabisplantextractsbyscreeningincellandanimalmodelsofparkinsonsdisease AT shimodalorimn identificationofminimumessentialtherapeuticmixturesfromcannabisplantextractsbyscreeningincellandanimalmodelsofparkinsonsdisease AT turnerhelen identificationofminimumessentialtherapeuticmixturesfromcannabisplantextractsbyscreeningincellandanimalmodelsofparkinsonsdisease AT stokesalexanderj identificationofminimumessentialtherapeuticmixturesfromcannabisplantextractsbyscreeningincellandanimalmodelsofparkinsonsdisease AT smallhowardandreal identificationofminimumessentialtherapeuticmixturesfromcannabisplantextractsbyscreeningincellandanimalmodelsofparkinsonsdisease AT ellisleed identificationofminimumessentialtherapeuticmixturesfromcannabisplantextractsbyscreeningincellandanimalmodelsofparkinsonsdisease |